pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 8·1 min read
save

UnitedHealth executives donate heavily to Rep. Katherine Clark as No Surprises Act debate intensifies

Sep 8, 2026·read at STAT ↗RegulatoryNeutral

UnitedHealth Group's senior leadership, including CEO Stephen Hemsley, recently made sizable campaign contributions to Rep. Katherine Clark of Massachusetts.

Clark, the House Democratic leader who just won a closely contested primary, received the donations as part of a broader cash influx from the insurer.

The contributions come amid a heated debate over the No Surprises Act, which aims to curb surprise medical billing, and UnitedHealth's role in that policy discussion.

The story was reported in STAT's Health Care Inc. newsletter, highlighting the intersection of health-care financing and politics.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: UnitedHealth’s Democrat investment, and surprise billing bloat debate”

read at STAT ↗
471 words · retrieved Sep 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA
topics
Breast CancerOncology

related stories

  • Aug 3Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaFierce Biotech
  • Jul 30Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsBioSpace
  • Jul 29Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBioPharma Dive
  • Jul 29Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationFierce Biotech
  • Jul 24Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaBioPharma Dive